Loading…
MINT-EZETIMIBE is a brand name for Ezetimibe, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: MINT-EZETIMIBE (Ezetimibe Tablets) is indicated as an adjunct to lifestyle changes, including diet, when the response to diet and other non-pharmacological measures alone has been inadequate. Primary Hypercholesterolemia MINT-EZETIMIBE, administered alone or with an HMG-CoA reductase inhibitor (statin), is indicated…
Verbatim from this product's HC label. Tap a section to expand.
1 Dosing Considerations • Patients should be placed on a standard cholesterol-lowering diet at least equivalent to the NCEP Adult Treatment Panel III (ATP III) TLC diet before receiving MINT-EZETIMIBE, and should continue on this diet during treatment with MINT-EZETIMIBE.
If appropriate, a program of weight control and physical exercise should be implemented. • Prior to initiating therapy with MINT-EZETIMIBE, secondary causes for elevations in plasma lipid levels should be excluded. A lipid profile should also be performed.
2 Recommended Dose and Dosage Adjustment The recommended dose of MINT-EZETIMIBE is 10 mg once daily orally, alone, with a statin, or with fenofibrate. MINT-EZETIMIBE can be taken with or without food at any time of the day but preferably at the same time each day.
4 Geriatrics). 3 Pediatrics).
Use in Patients with Hepatic Impairment:
No dosage adjustment is required in patients with mild hepatic insufficiency (Child-Pugh score 5 to 6). Treatment with MINT-EZETIMIBE is not recommended in patients with moderate (Child-Pugh score 7 to 9) or severe (Child-Pugh score >9) liver dysfunction (see 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic, Patients with Liver Impairment ).
Use in Patients with Renal Impairment:
No dosage adjustment is required for patients with renal impairment (see 7 WARNINGS AND PRECAUTIONS, Renal). 4 Drug-Drug Interactions, Cholestyramine). 4 Administration MINT-EZETIMIBE tablet is for oral administration. MINT-EZETIMIBE can be taken with or without food at any time of the day but preferably at the same time each day.
5 Missed Dose The recommended dosing regimen is one tablet, once daily. If a dose is missed, the patient should be counselled to resume the usual schedule of one tablet daily.
1 Dosing Considerations • Patients should be placed on a standard cholesterol-lowering diet at least equivalent to the NCEP Adult Treatment Panel III (ATP III) TLC diet before receiving MINT-EZETIMIBE, and should continue on this diet during treatment with MINT-EZETIMIBE.
If appropriate, a program of weight control and physical exercise should be implemented. • Prior to initiating therapy with MINT-EZETIMIBE, secondary causes for elevations in plasma lipid levels should be excluded. A lipid profile should also be performed.
2 Recommended Dose and Dosage Adjustment The recommended dose of MINT-EZETIMIBE is 10 mg once daily orally, alone, with a statin, or with fenofibrate. MINT-EZETIMIBE can be taken with or without food at any time of the day but preferably at the same time each day.
4 Geriatrics). 3 Pediatrics).
Use in Patients with Hepatic Impairment:
No dosage adjustment is required in patients with mild hepatic insufficiency (Child-Pugh score 5 to 6). Treatment with MINT-EZETIMIBE is not recommended in patients with moderate (Child-Pugh score 7 to 9) or severe (Child-Pugh score >9) liver dysfunction (see 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic, Patients with Liver Impairment ).
Use in Patients with Renal Impairment:
No dosage adjustment is required for patients with renal impairment (see 7 WARNINGS AND PRECAUTIONS, Renal).
Co-administration with Bile Acid Sequestrants:
MINT-EZETIMIBE should be administered either 2 MINT-EZETIMIBE(Ezetimibe Tablets) Page 6 of 35 Protected B / Protégé B hours or longer before or 4 hours or longer after administration of a bile acid sequestrant (see
, Immune 04/2025 7 WARNINGS AND PRECAUTIONS, Sensitivity/Resistance 04/2025 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ....................................................................................................
2 TABLE OF CONTENTS....................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION..............................................................................
4 1 INDICATIONS ....................................................................................................................... 1 Pediatrics....................................................................................................................
2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS ..........................................................................................................
4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................................................... 5 4 DOSAGE AND ADMINISTRATION ......................................................................................... 1 Dosing Considerations.................................................................................................
2 Recommended Dose and Dosage Adjustment............................................................. 4 Administration ............................................................................................................ 5 Missed Dose ...............................................................................................................
6 5 OVERDOSAGE ...................................................................................................................... 6 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ........................................ 6 7 WARNINGS AND PRECAUTIONS...........................................................................................
• MINT-EZETIMIBE is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
• The combination of MINT-EZETIMIBE with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases. • All statins and fenofibrate are contraindicated in pregnant and nursing women.
1 Pregnant Women). • Due to the presence of lactose in MINT-EZETIMIBE tables, use in patients with hereditary problems of galactose intolerance, glucose-galactose malabsorption or the Lapp lactase deficiency is also contraindicated (see 7 WARNINGS AND PRECAUTIONS, Sensitivity/Resistance)
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ezetimibe in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
1 Special Populations ..................................................................................................... 1 Pregnant Women........................................................................................................
2 Breastfeeding ............................................................................................................. 3 Pediatrics....................................................................................................................
4 Geriatrics .................................................................................................................... 9 8 ADVERSE REACTIONS ...........................................................................................................
1 Adverse Reaction Overview ........................................................................................ 26 15 MICROBIOLOGY […]